Baseline characteristics
| Characteristics | n=96 | Rate (%) |
|---|---|---|
| Age (years) [mean±SD] | 49.1±21,7 | |
| Body mass index BMI [median (range)] | 26.5 (17.3-50) | |
| FIGO stage (2009) | ||
| - IA1/IA2 | 8 | 8.3 |
| - IB1 | 71 | 74 |
| - IB2 | 7 | 7.3 |
| - IIA1 | 9 | 9.4 |
| - IIB | 1 | 1 |
| FIGO stage (2018) | ||
| - IA1/1A2 | 8 | 8.3 |
| - IB1 | 25 | 26 |
| - IB2 | 41 | 42.7 |
| - IB3 | 10 | 10.4 |
| - IIA1 | 8 | 8.3 |
| - IIB | 1 | 1 |
| Histological type | ||
| - Squamous | 53 | 55.2 |
| - Adenocarcinoma | 35 | 36.5 |
| - Adeno-squamous | 2 | 2.1 |
| - Others (*) | 6 | 6.25 |
| Type of surgery | ||
| - Radical hysterectomy | 89 | 92.7 |
| - Radical trachelectomy | 6 | 6.3 |
| - Other: radical colpectomy | 1 | 1 |
| Surgical approach | ||
| - LPS | 75 | 78.1 |
| - LPT | 15 | 15.6 |
| - Vaginal | 6 | 6.3 |
| SLN | ||
| - Performed | 67 | 69.8 |
| - Not performed | ||
| Surgical time (min) [mean±SD] | 248.3±56.8 | |
| Final FIGO stage (2009) | ||
| - IA1/1A2 | 9 | 9.4 |
| - IB1 | 69 | 71.9 |
| - IB2 | 9 | 9.4 |
| - IIA1 | 5 | 5.2 |
| - IIA2 | 1 | 1 |
| - IIB | 3 | 3.1 |
| Final FIGO stage (2018) | ||
| - IA1/1A2 | 9 | 9.4 |
| - IB1 | 19 | 19.8 |
| - IB2 | 39 | 40.6 |
| - IB3 | 9 | 9.4 |
| - IIA1 | 4 | 4.2 |
| - IIA2 | 2 | 2.1 |
| - IIB | 3 | 3.1 |
| - IIIC1 | 11 | 11.5 |
| - IIIC2 | 0 | 0 |
| Intraoperative complications | 12 | 12.5 |
| - Bowel injury | 2 | |
| - Urological injury | 7 | |
| - Vascular injury | 1 | |
| - Nerve injury | 2 | |
| - Others | 0 | |
| Short-term postoperative complications (<30 days) (Clavien-dindo) | ||
| - II | 17 | 17.7 |
| - III | 10 | 12.5 |
| - IV | 0 | 0 |
| - V | 0 | 0 |
| Medium/long-term postoperative complications (>30 days) (Clavien-dindo) | ||
| - II | 2 | 2.1 |
| - III | 7 | 7.3 |
| - IV | 1 | 1 |
| - V | 0 | 0 |
| Hospital stay [mean±SD] | 3.44±1.7 | |
| Mortality (30 days) | 0 | 0 |
(*) Others: small cell neuroendocrine carcinoma, lymphoepithelioma type carcinoma, clear cell carcinoma, adenosarcoma with sarcomatous growth and ”glassy cell” adenocarcinoma variant)